KalVista's sebetralstat nears FDA approval as a first-in-class oral treatment for hereditary angioedema. Read here for an ...

KalVista Pharmaceuticals (KALV) stock rises as the company secures a $22M+ licensing deal with Kaken Pharma (KKPCF) for Japan rights to its lead drug. Read more here.

Bank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has sold the Japanese rights to the drug to Kaken Pharmaceutical for $11 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pharmaceuticals announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization ...

KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), to Kaken Pharmaceutical in Japan. KalVista will be ...

CAMBRIDGE, Mass. & SALISBURY, England, March 31, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...